2006年至2012年中国北方肺结核患者临床分离株中对对氨基水杨酸耐药性的遗传决定因素。
Genetic determinants involved in p-aminosalicylic acid resistance in clinical isolates from tuberculosis patients in northern China from 2006 to 2012.
作者信息
Zhang Xiaobing, Liu Liguo, Zhang Yan, Dai Guangming, Huang Hairong, Jin Qi
机构信息
MOH Key Laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.
出版信息
Antimicrob Agents Chemother. 2015 Feb;59(2):1320-4. doi: 10.1128/AAC.03695-14. Epub 2014 Nov 24.
Abstract
p-Aminosalicylic acid (PAS) is an important compound for treating multidrug-resistant tuberculosis (TB). Previous studies showed that thyA mutations are often related to PAS resistance in clinical isolates. We performed a systematic analysis of isolate genotypes and detected mutations in three folate pathway genes (folC, thyA, and ribD) in 61.1% (127/208) of PAS-resistant isolates, including 11 double mutants. This result expands our knowledge about the distribution and frequency of mutations related to PAS resistance in mycobacterial clinical isolates.
摘要
对氨基水杨酸（PAS）是治疗耐多药结核病（TB）的一种重要化合物。先前的研究表明，thyA突变在临床分离株中常与对PAS耐药有关。我们对分离株基因型进行了系统分析，并在61.1%（127/208）的耐PAS分离株中检测到三个叶酸途径基因（folC、thyA和ribD）的突变，其中包括11个双突变体。这一结果拓展了我们对分枝杆菌临床分离株中与PAS耐药相关突变的分布和频率的认识。
相似文献
1
Genetic determinants involved in p-aminosalicylic acid resistance in clinical isolates from tuberculosis patients in northern China from 2006 to 2012.
Antimicrob Agents Chemother. 2015 Feb;59(2):1320-4. doi: 10.1128/AAC.03695-14. Epub 2014 Nov 24.
2
Determination of critical concentration for drug susceptibility testing of Mycobacterium tuberculosis against para-aminosalicylic acid with clinical isolates with thyA, folC and dfrA mutations.
Ann Clin Microbiol Antimicrob. 2022 Nov 5;21(1):48. doi: 10.1186/s12941-022-00537-z.
3
[Mutations in the thymidylate synthase gene is a major mechanism in the para-aminosalicylic acid resistance of M. tuberculosis].
Zhonghua Jie He He Hu Xi Za Zhi. 2007 Sep;30(9):683-5.
4
The folate pathway is a target for resistance to the drug para-aminosalicylic acid (PAS) in mycobacteria.
Mol Microbiol. 2004 Jul;53(1):275-82. doi: 10.1111/j.1365-2958.2004.04120.x.
5
Molecular genetics of para-aminosalicylic acid resistance in clinical isolates and spontaneous mutants of Mycobacterium tuberculosis.
Antimicrob Agents Chemother. 2009 May;53(5):2100-9. doi: 10.1128/AAC.01197-08. Epub 2009 Feb 23.
6
Whole genome sequencing reveals candidate genes involving in PAS resistance in M. Tuberculosis isolated from patients in Thailand.
World J Microbiol Biotechnol. 2023 Dec 7;40(1):32. doi: 10.1007/s11274-023-03834-7.
7
Molecular characterization of para-aminosalicylic acid resistant clinical isolates in southwestern China.
Infect Drug Resist. 2019 Jul 24;12:2269-2275. doi: 10.2147/IDR.S207259. eCollection 2019.
8
Multi-omics comparisons of p-aminosalicylic acid (PAS) resistance in folC mutated and un-mutated Mycobacterium tuberculosis strains.
Emerg Microbes Infect. 2019;8(1):248-261. doi: 10.1080/22221751.2019.1568179.
9
Thr202Ala in thyA is a marker for the Latin American Mediterranean lineage of the Mycobacterium tuberculosis complex rather than para-aminosalicylic acid resistance.
Antimicrob Agents Chemother. 2010 Nov;54(11):4794-8. doi: 10.1128/AAC.00738-10. Epub 2010 Aug 30.
10
Mycobacterium tuberculosis folate metabolism and the mechanistic basis for para-aminosalicylic acid susceptibility and resistance.
Antimicrob Agents Chemother. 2015 Sep;59(9):5097-106. doi: 10.1128/AAC.00647-15. Epub 2015 Jun 1.
引用本文的文献
1
Genetic diversity and transmission pattern of multidrug-resistant tuberculosis based on whole-genome sequencing in Wuhan, China.
Front Public Health. 2025 Jan 28;13:1442987. doi: 10.3389/fpubh.2025.1442987. eCollection 2025.
2
Advancing against drug-resistant tuberculosis: an extensive review, novel strategies and patent landscape.
Naunyn Schmiedebergs Arch Pharmacol. 2025 Mar;398(3):2127-2150. doi: 10.1007/s00210-024-03466-0. Epub 2024 Oct 8.
3
The T120P or M172V mutation on confers high level -aminosalicylic acid resistance in .
Emerg Microbes Infect. 2024 Dec;13(1):2374030. doi: 10.1080/22221751.2024.2374030. Epub 2024 Jul 24.
4
Competition between HPteGlu and HPtePAS Confers -Aminosalicylic Acid Resistance in .
Antibiotics (Basel). 2023 Dec 21;13(1):13. doi: 10.3390/antibiotics13010013.
5
Mutations in the promoter region of methionine transporter gene (Rv3253c) confer -aminosalicylic acid (PAS) resistance in .
mBio. 2024 Feb 14;15(2):e0207323. doi: 10.1128/mbio.02073-23. Epub 2024 Jan 5.
6
Whole genome sequencing reveals candidate genes involving in PAS resistance in M. Tuberculosis isolated from patients in Thailand.
World J Microbiol Biotechnol. 2023 Dec 7;40(1):32. doi: 10.1007/s11274-023-03834-7.
7
Association between mutations in a region and -aminosalicylic acid resistance in clinical isolates.
Emerg Microbes Infect. 2023 Dec;12(2):2276339. doi: 10.1080/22221751.2023.2276339. Epub 2023 Nov 29.
8
Heterologous production of the D-cycloserine intermediate O-acetyl-L-serine in a human type II pulmonary cell model.
Sci Rep. 2023 May 26;13(1):8551. doi: 10.1038/s41598-023-35632-4.
9
A pro-oxidant property of vitamin C to overcome the burden of latent infection: A cross-talk review with Fenton reaction.
Front Cell Infect Microbiol. 2023 Apr 19;13:1152269. doi: 10.3389/fcimb.2023.1152269. eCollection 2023.
10
Determination of critical concentration for drug susceptibility testing of Mycobacterium tuberculosis against para-aminosalicylic acid with clinical isolates with thyA, folC and dfrA mutations.
Ann Clin Microbiol Antimicrob. 2022 Nov 5;21(1):48. doi: 10.1186/s12941-022-00537-z.
本文引用的文献
1
Genetic diversity within Mycobacterium tuberculosis complex impacts on the accuracy of genotypic pyrazinamide drug-susceptibility assay.
Tuberculosis (Edinb). 2014 Jul;94(4):451-3. doi: 10.1016/j.tube.2014.04.002. Epub 2014 Apr 24.
2
High proportion of heteroresistance in gyrA and gyrB in fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates.
Antimicrob Agents Chemother. 2014 Jun;58(6):3270-5. doi: 10.1128/AAC.02066-13. Epub 2014 Mar 31.
3
Phylogenetic polymorphisms in antibiotic resistance genes of the Mycobacterium tuberculosis complex.
J Antimicrob Chemother. 2014 May;69(5):1205-10. doi: 10.1093/jac/dkt535. Epub 2014 Jan 23.
4
Binding pocket alterations in dihydrofolate synthase confer resistance to para-aminosalicylic acid in clinical isolates of Mycobacterium tuberculosis.
Antimicrob Agents Chemother. 2014;58(3):1479-87. doi: 10.1128/AAC.01775-13. Epub 2013 Dec 23.
5
WHO publishes Global tuberculosis report 2013.
Euro Surveill. 2013 Oct 24;18(43):20615.
6
para-Aminosalicylic acid is a prodrug targeting dihydrofolate reductase in Mycobacterium tuberculosis.
J Biol Chem. 2013 Aug 9;288(32):23447-56. doi: 10.1074/jbc.M113.475798. Epub 2013 Jun 18.
7
Co-occurrence of amikacin-resistant and -susceptible Mycobacterium tuberculosis isolates in clinical samples from Beijing, China.
J Antimicrob Chemother. 2013 Jul;68(7):1537-42. doi: 10.1093/jac/dkt082. Epub 2013 Mar 28.
8
Role of rpsA gene sequencing in diagnosis of pyrazinamide resistance.
J Clin Microbiol. 2013 Jan;51(1):382. doi: 10.1128/JCM.02739-12.
9
Para-aminosalicylic acid acts as an alternative substrate of folate metabolism in Mycobacterium tuberculosis.
Science. 2013 Jan 4;339(6115):88-91. doi: 10.1126/science.1228980. Epub 2012 Nov 1.
10
Importance of the genetic diversity within the Mycobacterium tuberculosis complex for the development of novel antibiotics and diagnostic tests of drug resistance.
Antimicrob Agents Chemother. 2012 Dec;56(12):6080-7. doi: 10.1128/AAC.01641-12. Epub 2012 Sep 24.
Zotero 插件